Mycophenolate mofetil oral - Azurity Pharmaceuticals
Alternative Names: MyhibbinLatest Information Update: 24 May 2024
At a glance
- Originator Azurity Pharmaceuticals
- Class Acyclic acids; Fatty acids; Small molecules
- Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
Most Recent Events
- 17 May 2024 Chemical structure information added
- 06 May 2024 Azurity Pharmaceuticals plans to launch mycophenolate mofetil for Renal transplant rejection, Heart transplant rejection and Liver transplant rejection (Prevention) (PO), in Q2 2024
- 01 May 2024 Registered for Heart transplant rejection (Combination therapy, In adolescents, In children, In infants, Prevention, In adults) in USA (PO)